ArticleOncoTargets and therapy2017
Primary site surgery for metastatic adrenocortical carcinoma improves survival outcomes: an analysis of a population-based database.
Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 25 citations in OpenAlex.
- Clinicopathologic Determinants of Overall Survival in Adrenocortical Carcinoma: A SEER-Based Population Study.Cancers · 2026Article
- Current evidence across the treatment spectrum of adrenocortical carcinoma: a comprehensive scoping review.Endocrine oncology (Bristol, England) · 2026Article
- Adjuvant radiation therapy improves outcome of patients with surgical resected adrenocortical carcinoma.Endocrine · 2025Article
- Surgery for advanced adrenal malignant disease: recommendations based on European Society of Endocrine Surgeons consensus meeting.The British journal of surgery · 2024Article
- Surgical Management of Metastatic Adrenocortical Carcinoma.World journal of surgery · 2024Article
- Article
- The prognosis difference between elderly and younger patients with adrenocortical carcinoma.Frontiers in genetics · 2022Article
- Adrenal Surgery for Synchronously Metastatic Adrenocortical Carcinoma: A Population-Based Analysis.World journal of surgery · 2021Article
- Adrenocortical Carcinoma: Updates of Clinical and Pathological Features after Renewed World Health Organisation Classification and Pathology Staging.Biomedicines · 2021Review
- Adrenocortical carcinoma in a patient with neurofibromatosis type 1: A case report.Caspian journal of internal medicine · 2021Article
- Management of Adrenocortical Carcinoma.Current oncology reports · 2019Review
- Development and validation of a nomogram for predicting cancer-specific survival in patients with Wilms' tumor.Journal of Cancer · 2019Article
- Nomograms to predict overall survival and cancer-specific survival in patients with adrenocortical carcinoma.Cancer management and research · 2018Article
- The impact of the lymph node density on overall survival in patients with Wilms' tumor: a SEER analysis.Cancer management and research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo define the survival effect of surgery of primary adrenal malignant lesions in metastatic adrenocortical carcinoma (ACC) patients. PATIENTS AND
methodsWe used the Surveillance, Epidemiology and End Results (SEER) database (1973-2014) to identify metastatic ACC patients (stage IV by using European Network for the Study of Adrenal Tumors stage classification). Correlated variables, including age, sex, race, tumor laterality, treatment modality, lymph node dissection, surgery of metastatic site, tumor size, and tumor stage, were extracted. Univariate and multivariate Cox regression analyses were used to define the efficacy of surgery on survival outcomes, including overall survival and cancer-specific survival of ACC.
resultsThere were 290 metastatic ACC patients identified from the database. The overall median survival time was 7 (95% CI, 6-8) months. Among these patients, 118 patients received primary site surgery and 172 patients did not. In both univariate and multivariate analyses, primary site surgery significantly improved both overall (hazard ratio 0.413, 95% CI, 0.299-0.571,
conclusionOur study suggests that primary site surgery in metastatic ACC patients significantly improved overall and cancer-specific survival. Further multicenter prospective studies are still needed to validate these outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.